Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
WYETH ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WYETH Mar-14 |
ACTAVIS Dec-18 |
WYETH/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,065 | 16,136 | - | |
Low | Rs | 553 | 10,824 | - | |
Sales per share (Unadj.) | Rs | 289.5 | 3,958.1 | - | |
Earnings per share (Unadj.) | Rs | 38.7 | -1,274.9 | - | |
Cash flow per share (Unadj.) | Rs | 39.9 | 417.1 | - | |
Dividends per share (Unadj.) | Rs | 145.00 | 0 | - | |
Avg Dividend yield | % | 17.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 118.5 | 16,325.5 | - | |
Shares outstanding (eoy) | m | 22.72 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 3.4 | 82.1% | |
Avg P/E ratio | x | 20.9 | -10.6 | -197.7% | |
P/CF ratio (eoy) | x | 20.3 | 32.3 | 62.7% | |
Price / Book Value ratio | x | 6.8 | 0.8 | 826.7% | |
Dividend payout | % | 374.7 | 0 | - | |
Avg Mkt Cap | Rs m | 18,381 | 4,483,446 | 0.4% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 359 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,898.1 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,091.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,577 | 1,316,478 | 0.5% | |
Other income | Rs m | 347 | 25,175 | 1.4% | |
Total revenues | Rs m | 6,925 | 1,341,653 | 0.5% | |
Gross profit | Rs m | 1,023 | 34,498 | 3.0% | |
Depreciation | Rs m | 27 | 562,766 | 0.0% | |
Interest | Rs m | 4 | 75,968 | 0.0% | |
Profit before tax | Rs m | 1,339 | -579,060 | -0.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,684 | 0.0% | |
Tax | Rs m | 460 | -7,338 | -6.3% | |
Profit after tax | Rs m | 879 | -424,038 | -0.2% | |
Gross profit margin | % | 15.6 | 2.6 | 593.7% | |
Effective tax rate | % | 34.3 | 1.3 | 2,709.0% | |
Net profit margin | % | 13.4 | -32.2 | -41.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,964 | 539,950 | 0.7% | |
Current liabilities | Rs m | 2,081 | 477,658 | 0.4% | |
Net working cap to sales | % | 28.6 | 4.7 | 605.0% | |
Current ratio | x | 1.9 | 1.1 | 168.5% | |
Inventory Days | Days | 35 | 20 | 179.2% | |
Debtors Days | Days | 278 | 66 | 418.6% | |
Net fixed assets | Rs m | 878 | 149,018 | 0.6% | |
Share capital | Rs m | 227 | 0 | - | |
Net worth | Rs m | 2,693 | 5,429,856 | 0.0% | |
Long term debt | Rs m | 25 | 1,912,049 | 0.0% | |
Total assets | Rs m | 4,842 | 8,488,101 | 0.1% | |
Interest coverage | x | 306.0 | -6.6 | -4,620.2% | |
Debt to equity ratio | x | 0 | 0.4 | 2.6% | |
Sales to assets ratio | x | 1.4 | 0.2 | 875.8% | |
Return on assets | % | 18.2 | -4.1 | -445.0% | |
Return on equity | % | 32.6 | -7.8 | -418.1% | |
Return on capital | % | 49.4 | -4.8 | -1,020.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,188 | 470,328 | 0.3% | |
From Investments | Rs m | 287 | 258,384 | 0.1% | |
From Financial Activity | Rs m | -4,296 | -807,224 | 0.5% | |
Net Cashflow | Rs m | -2,821 | -78,120 | 3.6% |
Compare WYETH With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare WYETH With: SYNCOM FORMULATIONS MEDPLUS HEALTH SERVICES HINDUSTAN BIOSCIE PFIZER SUVEN PHARMACEUTICALS
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.